)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Ardelyx
Ardelyx (ARDX) investor relations material
Ardelyx Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary3 Nov, 2026
Executive summary
Q3 product revenue was $125.5M, up 19% YoY; total revenue was $127.7M, up 16% YoY.
Net loss narrowed to $0.7M; cash, cash equivalents and short-term investments totaled $285.3M at September 30, 2026.
Priorities include accelerating IBSRELA, sustaining XPHOZAH momentum, advancing the pipeline and maintaining financial flexibility.
Financial highlights
Total product revenue was $125.5M vs. $105.5M in Q3 2025; total revenue was $127.7M vs. $110.3M.
Q3 net loss was $0.7M vs. $1.0M; operating income was $4.0M vs. $4.7M.
R&D expense was $25.2M vs. $18.1M; SG&A was $93.9M vs. $83.6M, reflecting pipeline and commercial investment.
9M revenue was $343.0M vs. $282.1M; net loss narrowed to $55.1M from $61.2M.
Outlook and guidance
Reaffirmed FY 2026 IBSRELA revenue guidance of $350M–$370M and XPHOZAH guidance of $110M–$120M; operating expenses expected below $500M.
IBSRELA guidance implies annual growth above 30% at the midpoint; long-term annual U.S. revenue target remains $1B.
Profitability remains targeted for 2027; ACCEL CIC Phase 3 topline results expected in H2 2027.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Ardelyx
- Profitability is on track for 2027, with strong growth, cash generation, and multiple expansion drivers.ARDX
Morgan Stanley 24th Annual Global Healthcare Conference - Profitability expected by 2027, driven by IBSRELA growth, payer strategy, and pipeline expansion.ARDX12th Annual Cantor Fitzgerald Global Healthcare Conference
- Q2 2026 revenue up 31% to $118.1M; net loss narrows, guidance updated for market shifts.ARDXQ2 2026
- IBSRELA and XPHOZAH are set for robust growth, targeting $1B and $750M revenues by 2029.ARDXJefferies Global Healthcare Conference 2026
- Q3 2025 revenue up 12% to $110.3M, led by IBSRELA's 92% growth and strong liquidity.ARDXQ3 2025
- Q3 revenue surged 74% year-over-year, led by strong IBSRELA and XPHOZAH sales.ARDXQ3 2024
- TDAPA application was declined to protect XPHOZAH access as legislative solutions are pursued.ARDXBusiness Update
- Q1 revenue surged 61% to $74.1M, but net loss widened to $41.1M on higher expenses.ARDXQ1 2025
- 2024 revenue hit $333.6M, net loss narrowed, and cash rose to $250.1M, supporting future growth.ARDXQ4 2024
Next Ardelyx earnings date
Jefferies Global Healthcare Conference17 Nov, 2026
Ardelyx
Next Ardelyx earnings date
Jefferies Global Healthcare Conference17 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Ardelyx Inc is a biopharmaceutical company engaged in discovering, developing, and commercializing novel treatments for patients with gastrointestinal and cardiorenal diseases. Their approach focuses on creating targeted, first-in-class, oral, small molecule therapies that address significant unmet medical needs. The company's flagship product candidate is tenapanor, aimed at treating irritable bowel syndrome with constipation. Furthermore, Ardelyx is advancing XPHOZAH in Phase III clinical trials for controlling serum phosphorus in patients with chronic kidney disease on dialysis, and other product candidates like RDX013 and RDX020 target hyperkalemia and metabolic acidosis, respectively. Ardelyx has formed strategic partnerships with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in various territories. Originally founded as Nteryx, Inc., the company rebranded to Ardelyx, Inc. in 2008 and is headquartered in Waltham, Massachusetts, with its shares listed on the NASDAQ.